Tremelimumab trial discontinued

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Pfizer Inc has discontinued a phase III trial of single-agent tremelimumab in patients with advanced melanoma after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy.

NEW YORK-Pfizer Inc has discontinued a phase III trial of single-agent tremelimumab in patients with advanced melanoma after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy. “We will continue to assess the study data to understand the clinical benefit seen in some patients who received tremelimumab,” said Pfizer’s Charles Baum, MD, PhD.

Articles in this issue
Proton therapy training offered
Editor of Blood reviews a very bloody movie
Artists take note: Oncology on Canvas accepting entries
PET affects treatment in over one-third of cancer cases
Expanded use of Axxent approved
Gardasil supplemental application gets priority review designation
Optical tomo/US monitors adjuvant chemo response
GIST patients resistant to imatinib/sunitinib respond to sorafenib
Sunitinib plus a taxane active in advanced breast cancer
Stanford V yields excellent outcomes in bulky, advanced HL
Monica Morrow joins Memorial Sloan-Kettering Cancer Center
Nereus initiates phase 1b trial of NPI-2358 in NSCLC patients
LHRH agonist use declines after reimbursement cuts
Palliative care helps pediatric pts at end of life
New colon screening guideline includes CT colonography
Related Videos
Experts on myeloma
Related Content
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.

Selecting Observation Vs Immunotherapy in Advanced Melanoma

April 2nd 2024
Article

Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.

FDA Clears Non-Invasive AI Device for Skin Cancer Detection

January 18th 2024
Article

The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.

On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

Individualized Neoantigen Therapy/Pembrolizumab Improves RFS in Melanoma

Individualized Neoantigen Therapy/Pembrolizumab Improves RFS in Melanoma

December 18th 2023
Article

mRNA-4157 is being evaluated in combination with pembrolizumab as part of the phase 2b KEYNOTE-942/mRNA-4157-P201 trial in patients with completely resected, high-risk, stage III to IV melanoma.

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.

mRNA Vaccine/Pembrolizumab Significantly Improves RFS in Resected Melanoma

October 23rd 2023
Article

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.